Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2014 to Q4 2025

Type / Class
Equity / Common Shares, no par value
Symbol
AUPH on Nasdaq
Shares outstanding
130,702,820
Price per share
$15.95
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
65,694,131
Total reported value
$725,976,226
% of total 13F portfolios
0%
Share change
+6,979,206
Value change
+$84,236,126
Number of holders
239
Price from insider filings
$15.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 7.3% $81,238,950 10,029,500 TANG CAPITAL MANAGEMENT, LLC 28 Feb 2025
ILJIN SNT Co., Ltd. 5% $57,509,241 6,535,141 Chin Kyu Huh 11 Aug 2025
ARMISTICE CAPITAL, LLC 4.5% $51,840,000 6,400,000 Armistice Capital, LLC 31 Dec 2024

As of 30 Sep 2025, 239 institutional investors reported holding 65,694,131 shares of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH). This represents 50% of the company’s total 130,702,820 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 8.7% 11,329,500 +13% 4.8% $125,190,975
BlackRock, Inc. 5.7% 7,448,858 -3.2% 0% $82,309,882
NEA Management Company, LLC 3% 3,969,834 0% 2.4% $43,866,666
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.6% 3,374,021 +214% 0.02% $37,282,932
STATE STREET CORP 2.1% 2,693,755 -3.6% 0% $29,765,993
MORGAN STANLEY 1.5% 1,946,785 -19% 0% $21,511,978
VANGUARD GROUP INC 1.2% 1,557,509 -9.5% 0% $17,210,474
GEODE CAPITAL MANAGEMENT, LLC 1.1% 1,485,700 -5.8% 0% $16,414,435
MARSHALL WACE, LLP 1.1% 1,483,132 +1273% 0.02% $16,388,610
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,449,600 +25% 0.02% $16,018,080
TWO SIGMA INVESTMENTS, LP 1% 1,341,067 +729% 0.02% $14,818,790
JACOBS LEVY EQUITY MANAGEMENT, INC 0.93% 1,219,451 +63% 0.05% $13,474,934
Qube Research & Technologies Ltd 0.88% 1,152,845 -7.2% 0.02% $12,738,937
JANUS HENDERSON GROUP PLC 0.8% 1,041,121 +370% 0.01% $11,504,388
D. E. Shaw & Co., Inc. 0.7% 909,922 +166% 0.01% $10,054,638
NORTHERN TRUST CORP 0.69% 896,447 -2.7% 0% $9,905,738
GOLDMAN SACHS GROUP INC 0.64% 842,027 +92% 0% $9,304,399
JUPITER ASSET MANAGEMENT LTD 0.63% 823,579 -12% 0.08% $9,100,548
Trexquant Investment LP 0.61% 801,083 +101% 0.09% $8,851,967
CITADEL ADVISORS LLC 0.54% 702,655 +497% 0.01% $7,764,338
JANE STREET GROUP, LLC 0.52% 677,253 +45% 0.01% $7,483,646
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 0.43% 565,956 0% 0.01% $6,253,814
Squarepoint Ops LLC 0.43% 555,697 +15% 0.01% $6,140,452
RICE HALL JAMES & ASSOCIATES, LLC 0.42% 542,555 -1.4% 0.33% $5,995,233
Connor, Clark & Lunn Investment Management Ltd. 0.41% 541,188 -17% 0.02% $5,980,127

Institutional Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 737,148 $11,672,326 -$130,061 $15.95 17
2025 Q3 65,694,131 $725,976,226 +$84,236,126 $11.05 239
2025 Q2 58,318,900 $494,168,918 -$31,810,462 $8.47 216
2025 Q1 62,001,205 $498,579,335 +$33,892,897 $8.04 210
2024 Q4 57,799,592 $519,061,476 +$4,097,220 $8.98 197
2024 Q3 57,639,569 $422,207,215 +$21,955,759 $7.33 180
2024 Q2 55,307,620 $315,754,570 +$4,958,367 $5.71 168
2024 Q1 54,674,386 $273,920,542 +$3,860,760 $5.01 173
2023 Q4 53,220,649 $478,436,427 +$38,734,205 $8.99 186
2023 Q3 50,339,448 $391,141,750 -$739,167 $7.77 194
2023 Q2 49,820,766 $482,543,239 -$1,739,141 $9.68 197
2023 Q1 49,994,676 $547,934,449 +$7,051,204 $10.96 182
2022 Q4 51,117,260 $220,815,199 -$24,246,473 $4.32 181
2022 Q3 55,353,711 $416,255,629 +$28,431,118 $7.52 177
2022 Q2 50,117,033 $503,590,633 +$74,385,031 $10.05 191
2022 Q1 42,164,731 $521,893,499 +$1,302,371 $12.38 176
2021 Q4 38,512,517 $881,056,850 -$105,784,806 $22.87 180
2021 Q3 43,124,514 $954,392,864 -$114,507 $22.13 160
2021 Q2 49,010,949 $635,371,815 -$42,000,595 $12.96 162
2021 Q1 52,072,235 $676,156,911 -$80,619,096 $12.99 163
2020 Q4 57,920,959 $801,022,755 -$114,549,555 $13.83 139
2020 Q3 64,784,594 $954,040,391 +$75,038,433 $14.73 144
2020 Q2 58,637,850 $953,206,339 -$24,791,270 $16.25 127
2020 Q1 60,307,130 $875,021,915 +$158,173,274 $14.51 122
2019 Q4 48,880,484 $990,406,662 +$509,187,869 $20.26 110
2019 Q3 25,474,542 $136,035,080 -$23,251,716 $5.34 68
2019 Q2 29,347,880 $193,099,929 -$3,061,002 $6.58 71
2019 Q1 29,823,940 $193,853,541 +$49,275,242 $6.50 76
2018 Q4 22,212,575 $151,471,995 +$3,053,577 $6.82 59
2018 Q3 21,500,016 $144,548,400 +$1,928,619 $6.64 62
2018 Q2 21,282,120 $121,759,408 -$2,409,149 $5.63 65
2018 Q1 21,720,891 $112,732,308 -$10,024,771 $5.19 63
2017 Q4 23,825,802 $107,940,708 -$515,812 $4.53 66
2017 Q3 23,438,674 $146,961,556 +$2,094,667 $6.27 59
2017 Q2 23,175,243 $142,270,544 -$8,837,055 $6.13 64
2017 Q1 23,813,237 $174,794,651 +$114,421,765 $7.34 71
2016 Q4 8,627,972 $18,126,000 +$8,662,521 $2.10 22
2016 Q3 4,238,270 $12,814,000 -$8,129,564 $3.01 14
2016 Q2 7,070,693 $20,093,000 +$878,266 $2.78 13
2016 Q1 6,743,443 $19,673,000 +$25,044 $2.92 16
2015 Q4 6,732,938 $16,753,741 -$1,105,844 $2.47 14
2015 Q3 7,110,273 $20,112,000 -$538,914 $2.84 11
2015 Q2 7,222,335 $21,748,000 -$1,342,201 $3.02 13
2015 Q1 7,607,904 $33,247,000 -$3,826,120 $4.37 11
2014 Q4 8,484,410 $30,665,000 +$8,984,489 $3.61 9
2014 Q3 6,016,277 $19,267,000 +$19,267,000 $3.20 8